Neuropathy in diabetes

ENDOCRINOLOGY, NEUROLOGY

Abstract

Diabetic polyneuropathy affects 30–50% of patients with diabetes mellitus. It encompasses several neuropathic syndromes, the most common being distal symmetrical polyneuropathy or ‘diabetic peripheral neuropathy’ (DPN). Risk factors for DPN include poor glycaemic control and drivers of macrovascular disease including hypertension. Strong evidence in humans and animals implicates nerve ischaemia as the cause of DPN. Despite several well-designed recent trials, no novel approved treatment with unequivocal effects on nerve function decline in DPN has emerged. Painful DPN affects about a quarter of those with diabetes, produces considerable disability and is challenging to assess and manage. First-line therapies are tricyclic antidepressants, serotoninnoradrenaline reuptake inhibitors (e.g. duloxetine) and anticonvulsants (e.g. pregabalin, gabapentin). Second-line drugs include opioids. Diabetic autonomic neuropathy also results in considerable morbidity, reduced quality of life and increased mortality. It can involve cardiovascular, gastrointestinal, urogenital, pupillomotor, thermoregulatory and sudomotor function. Although counselling and non-pharmacological interventions are of some use, more severely afflicted patients require pharmacological intervention.

Keywords

Autonomic neuropathy

diabetic neuropathy

diabetic peripheral neuropathy

distal symmetrical polyneuropathy

MRCP

painful diabetic neuropathy

DOWNLOAD